Different dosing strategies of colistin for treating infections from drug-resistant bacteria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates various dosing strategies of colistin, a last-resort antibiotic, to treat infections caused by multidrug-resistant Gram-negative bacteria in critically ill patients. The study focuses on patients in intensive care units who are infected with pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa. By comparing the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) dosing strategies, the trial aims to determine the most effective approach to combat these infections. The study is designed to enhance treatment outcomes for patients suffering from severe infections due to antibiotic-resistant bacteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients age ≥ 18 years old.
* Patients who will be treated with CMS for MR GNB infections.
* Patients who are admitted to the ICUs.

Exclusion Criteria:

* Known hypersensitivity to colistin.
* Pregnant and lactating women.
* Patients who are treated with colistin for \< 24 hours.
* Patients with myasthenia gravis or concomitant anesthetics or neuromuscular blocking drugs.

Where it's running

• King Fahad Specialist Hospital
  Buraidah, Saudi Arabia Recruiting

Study contacts

• Principal investigator: Mohamed E Shams, Professor — Mansoura University
• Study coordinator: Abdulmajeed S Alharbi, Master
• Email: majeed4440@hotmail.com
• Phone: 00966503984099

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CD19/BCMA UCART for B cell–related autoimmune diseases

  This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07586267

• Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease

  This Phase 1 study will test a donor-derived CAR‑T therapy that targets CD19 and BCMA to try to reset the immune system in people with refractory B‑cell autoimmune diseases such as SLE, IgA nephropathy, systemic sclerosis, and resistant nephrotic syndrome.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07507201

• Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases

  This study will try a single infusion of off‑the‑shelf CAR T cells that target CD19 and BCMA to treat people with B‑cell–mediated autoimmune diseases such as lupus, IgA nephropathy, and drug‑resistant nephrotic syndrome.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07305116

• Using CAR-NK cells to treat autoimmune diseases like lupus and nephrotic syndrome

  This study is testing a new treatment using CAR-NK cells to see if it can help people with autoimmune diseases like lupus and nephrotic syndrome feel better.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT06792799

• CAR-T cell therapy for treating multi-drug resistant nephrotic syndrome

  This study is testing a new CAR-T cell therapy to see if it can help children and adults with hard-to-treat nephrotic syndrome feel better and avoid kidney failure.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT06553898

• New six-month regimen for MDR-TB in France using BPaLM or BPaLC/BPaLM+Clofazimine

  This trial tests whether a six-month, bedaquiline-containing treatment strategy for rifampicin-resistant TB works as well as the long traditional regimens used in France by comparing outcomes to a historical cohort.

  Recruiting at 4 sites Phase 3 Assistance Publique - Hôpitaux de Paris · Amiens and 4 other locations · NCT07486024

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.